Processa Pharmaceuticals, Inc. — Director's Dealing 2022

Aug 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-08-05

Reporting Person: Young David (Director, President & CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-05	Common Stock	M	7601	—	Acquired	389565	Direct
2022-08-05	Common Stock	F	2531	$3.17	Disposed	387034	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	573568	Indirect
Common Stock	694591	Indirect
Common Stock	37504	Indirect

Footnotes

F1: Vesting of time-based restricted shares.